Michael Weber

Q: What Schools Are Affiliated With Michael Weber

Michael Weber is affiliated with the following schools: University of California, Berkeley, Haverford College, University of California, San Diego, Stanford University, University of Virginia

Michael Weber's AcademicInfluence.com Rankings

Michael Weber

Biology

#15337

World Rank

#19293

Historical Rank

Microbiology

#1022

World Rank

#1140

Historical Rank

biology Degrees

Download Badge

Biology

Michael Weber's Degrees

Bachelors Microbiology University of California, Berkeley
Masters Microbiology Stanford University

Why Is Michael Weber Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Weber's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers (1999) (1632)
Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras (1994) (721)
Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-Type Plasminogen Activator-Stimulated Cells in an Integrin-Selective Manner (1999) (333)
Role of a Mitogen-activated Protein Kinase Pathway in the Induction of Phase II Detoxifying Enzymes by Chemicals* (1999) (295)
PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation (2003) (273)
Akt-Dependent and -Independent Survival Signaling Pathways Utilized by Insulin-Like Growth Factor I (1998) (267)
Androgen Receptor Phosphorylation (2002) (250)
Rac-PAK Signaling Stimulates Extracellular Signal-Regulated Kinase (ERK) Activation by Regulating Formation of MEK1-ERK Complexes (2002) (238)
Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E (1998) (230)
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. (2003) (217)
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. (2006) (189)
Epinephrine Protects Cancer Cells from Apoptosis via Activation of cAMP-dependent Protein Kinase and BAD Phosphorylation* (2007) (176)
Control of Lytic Function by Mitogen-activated Protein Kinase/Extracellular Regulatory Kinase 2 (ERK2) in a Human Natural Killer Cell Line: Identification of Perforin and Granzyme B Mobilization by Functional ERK2 (1998) (173)
Ras signaling in prostate cancer progression (2004) (153)
Urokinase-type Plasminogen Activator Stimulates the Ras/Extracellular Signal-regulated Kinase (ERK) Signaling Pathway and MCF-7 Cell Migration by a Mechanism That Requires Focal Adhesion Kinase, Src, and Shc (2000) (147)
Mitogen-Activated Protein Kinase Feedback Phosphorylation Regulates MEK1 Complex Formation and Activation during Cellular Adhesion (2004) (142)
The current state of preclinical prostate cancer animal models (2008) (136)
Identification of Novel ERK2 Substrates through Use of an Engineered Kinase and ATP Analogs* (2003) (120)
Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. (2006) (119)
Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. (2004) (106)
Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. (2003) (90)
A Mammalian Scaffold Complex That Selectively Mediates MAP Kinase Activation (1998) (90)
RACK1 Targets the Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway To Link Integrin Engagement with Focal Adhesion Disassembly and Cell Motility (2007) (85)
The Androgen Receptor Acetylation Site Regulates cAMP and AKT but Not ERK-induced Activity* (2004) (85)
The state of melanoma: challenges and opportunities (2016) (79)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. (2017) (69)
Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. (2004) (65)
Leucine-zipper motif update (1989) (61)
Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer (2011) (61)
Direct Tumor Lysis by NK Cells Uses a Ras-Independent Mitogen-Activated Protein Kinase Signal Pathway 1 (2000) (60)
Biochemical and Biological Functions of the N-Terminal, Noncatalytic Domain of Extracellular Signal-Regulated Kinase 2 (2001) (56)
Extracellular Signal-Regulated Kinase 2 (ERK2) Phosphorylation Sites and Docking Domain on the Nuclear Pore Complex Protein Tpr Cooperatively Regulate ERK2-Tpr Interaction (2008) (54)
The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. (2009) (52)
Decreased adherence to the substrate in Rous sarcoma virus-transformed chicken embryo fibroblasts (1977) (48)
Inhibition of protease activity in cultures of rous sarcoma virus-transformed cells: Effect on the transformed phenotype (1975) (47)
Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms (2013) (45)
Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. (2007) (43)
Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. (2002) (43)
Discovery of PDK1 Kinase Inhibitors with a Novel Mechanism of Action by Ultrahigh Throughput Screening (2010) (43)
Dissociation of transformation parameters using temperature-conditional mutants of Rous sarcoma virus (1979) (36)
c-Raf-mediated Inhibition of Epidermal Growth Factor-stimulated Cell Migration* (1999) (34)
MEK partner 1 (MP1): Regulation of oligomerization in MAP kinase signaling (2005) (33)
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors (2008) (32)
Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma (2012) (31)
Rap2 regulates androgen sensitivity in human prostate cancer cells (2007) (30)
The reorientation of cell nucleus promotes the establishment of front-rear polarity in migrating fibroblasts. (2013) (30)
Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells (2006) (29)
Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) (2013) (28)
Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions (2014) (27)
Mitogen-Activated Protein Kinases: Specific Messages from (1999) (24)
Hydrolase and serum treatment of normal chick embryo cells: Effects on hexose transport (1975) (21)
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas (2015) (20)
PLASMIN-ACTIVATED PRODRUGS FOR CANCER CHEMOTHERAPY. 2. SYNTHESIS AND BIOLOGICAL ACTIVITY OF PEPTIDYL DERIVATIVES OF DOXORUBICIN (1983) (16)
Symmetry breaking in spreading RAT2 fibroblasts requires the MAPK/ERK pathway scaffold RACK1 that integrates FAK, p190A-RhoGAP and ERK2 signaling. (2016) (14)
Identifying specific kinase substrates through engineered kinases and ATP analogs. (2004) (11)
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma (2015) (10)
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. (2014) (10)
Plasminogen activator in normal and tumor‐bearing mice (1983) (8)
Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199) (2015) (5)
Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) (2013) (5)
Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma (2016) (5)
Signal Transduction by the Ras–MAP Kinase Pathway in Prostate Cancer Progression (2008) (4)
Phosphorylation ofa 36,000 MrCellular Protein inCells Infected withPartial Transformation Mutants ofRous Sarcoma Virus (1982) (4)
Extrinsic Interactions in the Microenvironment In Vivo Activate an Antiapoptotic Multidrug-Resistant Phenotype in CLL. (2021) (4)
Activation of Mitogen-Activated Protein Kinase Associated with Prostate Cancer Progression 1 (1999) (3)
Abstract 695: p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling (2014) (3)
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies. (2012) (3)
Abstract 5633: Co-targeting the IGF1R pathway and compensatory signaling enhances cytotoxicity in head and neck cancer. (2013) (3)
Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of kinase-associated substrates. (2007) (2)
Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of substrates in cell lysates with exogenous kinase. (2007) (1)
Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Generation of [{gamma}-32P]ATP Analog from ADP Analog. (2007) (1)
Advances in Brief Antiapoptotic Signaling in LNCaP Prostate Cancer Cells : A Survival Signaling Pathway Independent of Phosphatidylinositol 3 *-Kinase and Akt / Protein Kinase B 1 (1999) (1)
Abstract B40: Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist ABT-199 in mantle cell lymphoma and chronic lymphocytic leukemia: Molecular analysis reveals mechanisms of target interactions. (2015) (1)
Constitutive Phosphorylation oftheReceptor forInsulinlike Growth Factor IinCells Transformed bythesrcOncogene (1990) (1)
Abstract 1650: Targeting of compensatory signaling pathways identified in a synthetic lethal screen leads to synergistic growth inhibition in bladder cancer cells (2010) (1)
Raffling off the Effectors of Ras (2003) (1)
Kinase Signal Pathway Ras-Independent Mitogen-Activated Protein Direct Tumor Lysis by NK Cells Uses a (2000) (0)
Abstract 3031: Diverse microenvironmental agonists promote a multi drug tolerant persister phenotype CLL and MCL (2019) (0)
Abstract B29: Combinatorial screens with targeted inhibitors reveal diverse compensatory responses and mechanisms of adaptive resistance to therapy (2013) (0)
Abstract 3400: Small molecule biological screens and global analytical approaches reveal the complexity of cancer cell signaling networks and the challenge of personalized medicine. (2013) (0)
Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (2016) (0)
Abstract 2933: Synthetic lethal screening: A pathway for rational combinatorial therapies for cancer (2012) (0)
Book Review:Advances in Viral Oncology. Volume 1: Oncogene Studies. George Klein (1983) (0)
Abstract 4885: Diverse microenvironmental agonists inducede novoresistance to Bcl-2 and BTK targeted combination therapy and cancer cell proliferation in B cell malignancies (2018) (0)
Androgen Receptor Regulate the Tyrosine Phosphorylation and Function of the Receptor for Activated C Kinase 1 ( RACK 1 ) and Src (2006) (0)
Resistance to EGFR Kinase Inhibitor PD158780 in Head and Neck Cancer Cell Lines (2004) (0)
Genetic Analysis of Transformation by the src Oncogene (2020) (0)
Abstract 2381: Loss of S6K2 perturbs redox balance and fatty acid metabolism, leading to oxidative cell death (2018) (0)
PLASMIN-ACTIVATED PRODRUGS FOR CANCER CHEMOTHERAPY. 1. SYNTHESIS AND BIOLOGICAL ACTIVITY OF PEPTIDYLACIVICIN AND PEPTIDYLPHENYLENEDIAMINE MUSTARD (1983) (0)
Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia (2020) (0)
TheCurrent State of Preclinical ProstateCancerAnimalModels (2008) (0)
Abstract 08: Soluble agonists in the in vivo macroenvironment generate phenotypic de novo resistance to BTK/Bcl-2 targeted therapies in diverse B-cell malignancies (2017) (0)
Phosphorylation and activation of egf receptors in cells transformed by the src oncogene (1990) (0)
Proteins antigenically related to th, transporter in normal and Rous sa) chicken embryo fibroblasts (membrane alterations/malignant transformation) (2016) (0)
A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (2018) (0)
Abstract 937: The PP2A activation using a small molecule agonist triggers apoptosis by releasing mitochondrial permeability transition pores in multi-drug resistant leukemic B cells (2021) (0)
Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas (2018) (0)
Abstract 3843: Rational selection of combinatorial therapeutic targets for melanoma identified by synthetic lethal screening with small molecule inhibitors (2010) (0)
Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Identification of a Mutant Kinase/ATP Analog Pair. (2007) (0)
Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma (2021) (0)
Abstract 4166: Integrated molecular profiling of melanoma cell lines reveals genotype-drug phenotype associations giving insight on development of combination therapies (2014) (0)
Phosphorylation andActivation ofEpidermal GrowthFactor Receptors inCells Transformed bythesrcOncogene (1991) (0)
Advances in Brief Smac Is Required for Cytochrome c-induced Apoptosis in Prostate Cancer LNCaP Cells 1 (2001) (0)
Protease-activated "prodrugs" for c (plasminogen activator/plasmin/fibrinolysis/antineoplastic agent! (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael Weber?

Michael Weber is affiliated with the following schools: